← Back to Search

SMART-3RP Group Intervention for Quality of Life

N/A

Waitlist Available

Led By Lara Traeger, PhD

Research Sponsored by Massachusetts General Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 12 weeks

Awards & highlights

Study Summary

This trial tests whether a mind-body intervention can help people in retirement communities become more resilient and flourish.

Eligible Conditions

Quality of Life
Stress

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Flourishing: Flourishing Measure (FM)

Resilience: Current Experiences Scale (CES)

Secondary outcome measures

Community well-being: Community Well Being Survey (CWB)

Coping self-efficacy: Measure of Current Status - Part A (MOCS-A)

Physical symptoms: Condensed Memorial Symptom Assessment Scale (CMSAS)

+3 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: SMART-3RP Group InterventionExperimental Treatment1 Intervention

Residents will participate in 9 structured weekly group sessions which incorporates stress management and relaxation training upon enrollment.

Group II: Waitlist Control Group InterventionActive Control1 Intervention

Residents will participate in 9 structured weekly group sessions which incorporates stress management and relaxation training after the final survey time point.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

SMART-3RP Group Intervention

2022

N/A

~290

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor

2,928 Previous Clinical Trials

13,198,067 Total Patients Enrolled

Lara Traeger, PhDPrincipal InvestigatorMassachusetts General Hospital

3 Previous Clinical Trials

135 Total Patients Enrolled

Media Library

SMART-3RP Group Intervention Clinical Trial Eligibility Overview. Trial Name: NCT05438134 — N/A

Quality of Life Research Study Groups: Waitlist Control Group Intervention, SMART-3RP Group Intervention

Quality of Life Clinical Trial 2023: SMART-3RP Group Intervention Highlights & Side Effects. Trial Name: NCT05438134 — N/A

SMART-3RP Group Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT05438134 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent is this research endeavor being pursued by participants?

"Affirmative. Based on the information available online, this clinical trial is looking to recruit 360 volunteers from a single centre and has been active since June 24th 2022."

Answered by AI

What are the main aims of this investigation?

"This trial will be conducted over a period of up to 12 weeks, with its primary goal being the assessment of Flourishing Measure (FM). Secondary objectives include an evaluation of Condensed Memorial Symptom Assessment Scale (CMSAS) scores in order to measure physical symptoms; Patient Health Questionnaire 4 (PHQ4) scores which indicate psychological distress; and Measure of Current Status - Part A (MOCS-A), used as a gauge for coping self-efficacy."

Answered by AI

Is this experiment open for enrollment?

"The data accessible via clinicaltrials.gov demonstrates that this medical trial, which was first posted on June 24th 2022, is currently recruiting participants. The listing has been recently updated as of July 6th 2022."

Answered by AI